Commercial Manufacturing Agreement Sample Contracts

AutoNDA by SimpleDocs
BACKGROUND
Commercial Manufacturing Agreement • April 4th, 2008 • Xanodyne Pharmaceuticals Inc • Pharmaceutical preparations • New York
Lonza and bluebird bio, Inc., Establish a Long-term Commercial Manufacturing Agreement for Lenti-D™ and LentiGlobin™ Drug Products
Commercial Manufacturing Agreement • June 9th, 2016 • Bluebird Bio, Inc. • Biological products, (no disgnostic substances)

This agreement follows a successful multi-year clinical manufacturing relationship and provides bluebird bio with a path to commercial supply including dedicated production suites within Lonza’s state-of-the-art facility. This facility is currently under construction for the clinical and commercial supply of viral vectors and virally-modified cell therapy products.

COMMERCIAL MANUFACTURING AGREEMENT Salix Pharmaceuticals, Inc., Mesalamine Controlled Release Capsules
Commercial Manufacturing Agreement • August 17th, 2009 • Salix Pharmaceuticals LTD • Pharmaceutical preparations • Delaware

This Commercial Manufacturing Agreement (“Agreement”) is made effective as of this 9th day of September, 2008 (“Effective Date”), by and between Salix Pharmaceuticals, Inc., a California corporation, with a place of business at 1700 Perimeter Park Drive, Morrisville, NC, 27560 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”).

EX-10.47 4 d291060dex1047.htm COMMERCIAL MANUFACTURING AGREEMENT CERTAIN MATERIAL (INDICATED BY AN ASTERISK) HAS BEEN OMITTED FROM THIS DOCUMENT PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE...
Commercial Manufacturing Agreement • May 5th, 2020 • Puerto Rico

THIS AGREEMENT is executed as of this 19th day of December, 2006 and effective as of June 1, 2006 (the “Effective Date”), by and between MOVA Pharmaceutical Corporation (“MOVA”), a corporation organized under the laws of the Commonwealth of Puerto Rico, having its principal place of business at Villa Blanca Industrial Park, State Road No. 1, Km. 34.5,Caguas, Puerto Rico, and Depomed, Inc. (“DEPOMED”), a corporation organized under the laws of the State of California, having its principal place of business at 1360 O’Brien Drive, Menlo Park, California 94025. MOVA and DEPOMED each shall sometimes be referred to herein sometimes as a “Party” and collectively as the “Parties.”

EX-10.75 3 dex1075.htm COMMERCIAL MANUFACTURING AGREEMENT [ * ] = Certain information on this document has been redacted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the...
Commercial Manufacturing Agreement • May 5th, 2020 • New York

This Commercial Manufacturing Agreement (“Agreement”) is made as of this 10th day of September, 2009 (“Effective Date”), by and between InterMune, Inc., a Delaware corporation, with a place of business at 3280 Bayshore Blvd., Brisbane, CA 94005 (“Client”), and Catalent Pharma Solutions, LLC, a Delaware limited liability company with a place of business at 14 Schoolhouse Road, Somerset, New Jersey 08873 (“Catalent”).

AMENDING AGREEMENT
Commercial Manufacturing Agreement • May 8th, 2014 • Insmed Inc • Pharmaceutical preparations • New York

This Amending Agreement (this “Amending Agreement”) is entered into and effective this 13th day of March, 2014 (the “Effective Date”), by and between Therapure Biopharma Inc. (“Therapure”), a Canadian corporation with its principal place of business in Mississauga, Ontario and Insmed Incorporated (“Insmed”), a Virginia corporation, having its principal office at 9 Deer Park Drive, Suite C, Monmouth Junction, New Jersey. Each of Therapure and Insmed is referred to herein as a “party” and collectively as the “parties”.

COMMERCIAL MANUFACTURING AGREEMENT 1
Commercial Manufacturing Agreement • May 6th, 2015 • Siga Technologies Inc • Pharmaceutical preparations

THIS 2015 AMENDMENT TO COMMERCIAL MANUFACTURING AGREEMENT (the “2015 Amendment”), dated as of __ __________ 2015, is by and among SIGA Technologies, Inc., a Delaware corporation, having a place of business at 660 Madison Avenue, Suite 1700, New York, NY, 10065 (“Customer”), and Albemarle Corporation, a Virginia corporation, with a place of business at 451 Florida Street, Baton Rouge, LA, 70801 (“Albemarle”).

COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • March 16th, 2006 • Collagenex Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey

This Commercial Manufacturing Agreement (“Agreement”) is made this 30th day of December, 2005, by and between Cardinal Health PTS, LLC, having a place of business at 14 Schoolhouse Road, Somerset, NJ 08873 (“Cardinal Health”) and CollaGenex Pharmaceuticals, Inc. (“Client”), having its principal place of business at 41 University Drive, Suite 200, Newtown, PA 18940.

COMMERCIAL MANUFACTURING AGREEMENT (AVACOPAN)
Commercial Manufacturing Agreement • November 9th, 2020 • ChemoCentryx, Inc. • Pharmaceutical preparations

THIS AGREEMENT (“Agreement”) is made and entered into as of August 17, 2020 (the “Effective Date”) by and between ChemoCentryx, Inc. a Delaware corporation, with offices at 850 Maude Avenue, Mountain View, CA 94043 (“Customer”), and Hovione LLC, with a mailing address at 40 Lake Drive, East Windsor, New Jersey 08520 (“Hovione”).

Addendum #3 to Commercial Manufacturing Agreement
Commercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations

This Addendum to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective the 2nd day of July, 2014 by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and customer dated August 25, 2011, as amended December 21, 2012 and July 1, 2013 (the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.

Addendum to Commercial Manufacturing Agreement
Commercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations

This Addendum to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective this ____ day of _____________, 2012, by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and Customer dated August 25, 2011 (the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.

Contract
Commercial Manufacturing Agreement • March 17th, 2008 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)

NOTE: CERTAIN CONFIDENTIAL INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT AND REPLACED BY "[*]". A COMPLETE COPY OF THIS DOCUMENT INCLUDING THE CONFIDENTIAL INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations • Delaware

This COMMERCIAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into effective as of __________, 2011 (the “Effective Date”), by and between SIGA Technologies, Inc., a Delaware corporation (“Customer”), having a place of business at 35 E. 62nd Street, New York, NY, 10065, and Albemarle Corporation, a Virginia corporation (“Albemarle”), having a place of business at 451 Florida Street, Baton Rouge, Louisiana 70801. Each of Customer and Albemarle is sometimes referred to herein as a “Party” and collectively as the “Parties”.

COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • March 6th, 2019 • Siga Technologies Inc • Pharmaceutical preparations • Delaware

This COMMERCIAL MANUFACTURING AGREEMENT (this “Agreement”) is entered into effective as of October 1, 2018 (the “Effective Date”), by and between SIGA Technologies, Inc., a Delaware corporation (“Customer”), having a place of business at 31 East 62nd Street, New York, NY, 10065, and Albemarle Corporation, a Virginia corporation (“Albemarle”), having a place of business at 4350 Congress Street, Suite 700, Charlotte, North Carolina 28209. Each of Customer and Albemarle is sometimes referred to herein as a “Party” and collectively as the “Parties”.

MOVA Pharmaceutical Corporation and Depomed, Inc. COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • March 16th, 2007 • Depomed Inc • Pharmaceutical preparations • Puerto Rico

THIS AGREEMENT is executed as of this 19th day of December, 2006 and effective as of June 1, 2006 (the “Effective Date”), by and between MOVA Pharmaceutical Corporation (“MOVA”), a corporation organized under the laws of the Commonwealth of Puerto Rico, having its principal place of business at Villa Blanca Industrial Park, State Road No. 1, Km. 34.5,Caguas, Puerto Rico, and Depomed, Inc. (“DEPOMED”), a corporation organized under the laws of the State of California, having its principal place of business at 1360 O’Brien Drive, Menlo Park, California 94025. MOVA and DEPOMED each shall sometimes be referred to herein sometimes as a “Party” and collectively as the “Parties.”

AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • November 19th, 2013 • Pharmacyclics Inc • Pharmaceutical preparations
Contract
Commercial Manufacturing Agreement • November 9th, 2012 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)

NOTE: CERTAIN CONFIDENTIAL INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT AND REPLACED BY "[*]". A COMPLETE COPY OF THIS DOCUMENT INCLUDING THE CONFIDENTIAL INFORMATION HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.

ADDENDUM 2 TO COMMERCAIL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • November 4th, 2014 • Siga Technologies Inc • Pharmaceutical preparations

This Addendum 2 to Commercial Manufacturing Agreement, (this “Addendum”) is entered into and effective the 1st day of July, 2013 by and between Albemarle Corporation, (hereinafter “Albemarle”); and SIGA Technologies, Inc. (hereinafter “Customer”), to addend, amend and/or supplement that certain Commercial Manufacturing Agreement between Albemarle and customer dated August 25, 2011, as amended December 21, 2012 (collectively the “Commercial Manufacturing Agreement”). All capitalized terms used herein and not defined shall have the meaning set forth in the Commercial Manufacturing Agreement.

AMENDING AGREEMENT
Commercial Manufacturing Agreement • October 29th, 2020 • INSMED Inc • Pharmaceutical preparations • New York

This Amending Agreement (this “Amending Agreement”) is entered into and effective this 13th day of March, 2014 (the “Effective Date”), by and between Therapure Biopharma Inc. (“Therapure”), a Canadian corporation with its principal place of business in Mississauga, Ontario and Insmed Incorporated (“Insmed”), a Virginia corporation, having its principal office at 9 Deer Park Drive, Suite C, Monmouth Junction, New Jersey. Each of Therapure and Insmed is referred to herein as a “party” and collectively as the “parties”.

AMENDMENT NUMBER TWO TO AMENDING AGREEMENT
Commercial Manufacturing Agreement • May 3rd, 2011 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)

WHEREAS, the Parties have entered into a COMMERCIAL MANUFACTURING AGREEMENT dated as of OCTOBER 18, 2002 (hereinafter, the "AGREEMENT") for the manufacture of NPS ALLELIX proprietary product ALX-11 (also known as PREOS®), for which the active ingredient is recombinant human parathyroid hormone eighty-four (84) amino acids ("rhPTH"); and

AMENDMENT ONE TO COMMERCIAL MANUFACTURING AGREEMENT
Commercial Manufacturing Agreement • August 14th, 2014 • Pharmacyclics Inc • Pharmaceutical preparations
AutoNDA by SimpleDocs
COMMERCIAL MANUFACTURING AGREEMENT between NPS Pharmaceuticals, Inc. and Vetter Pharma International GmbH Dated as of December 21, 2009
Commercial Manufacturing Agreement • January 15th, 2013 • NPS Pharmaceuticals Inc • Biological products, (no disgnostic substances)

THIS QUALITY AGREEMENT, made and entered into as of the Commencement Date of the Commercial Manufacturing Agreement and attached thereto as Appendix 12 (the “QA”), by and between NPS and Vetter.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!